The Patented Medicine Prices Review Board (PMPRB) today, Ocober 6, 2022, released its draft PMPRB Guidelines with a 60-day consultation period running until December 5, 2022. 

PMPRB maintains that final Guidelines will be issued by end of this year and previously indicated its intent for new Guidelines to be implemented effective January 1, 2023. These timelines appear optimistic if the PMPRB is conducting meaningful consultations with stakeholders.   

In the coming days and weeks, PDCI will be posting an overview of the proposed Guidelines, holding an industry webinar assessing the impact on industry and, as with past consultations, hosting a public submissions landing page where all stakeholders can post their submissions once they are submitted to the PMPRB. 

And as always, PDCI experts will be assisting clients with impact analyses for portfolios and individual new or recent patented medicines, providing strategic advice and assisting clients to draft their comments and responses to the draft Guidelines. 

For more information, please contact Dylan Lamb-Palmer at Dylan.LambPalmer@PDCI.ca